SCHEMBL3464664

SCHEMBL3464664

CC(C)(C)C(=O)NCC(O)CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
DRD3 P35462 1/20 0.35
SLC6A3 Q01959 1/20 0.35
ALDH1A1 P00352 2/20 0.33
EGFR P00533 1/20 0.33
SRC P12931 1/20 0.33
POLB P06746 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA14 Q9ULX7 1/20 0.32
PTGS1 P23219 1/20 0.32
KCNH2 Q12809 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25590205 1.00 LMNA (0.36) LMNACYP2C19HIF1ADRD3SLC6A3
SCHEMBL26198162 1.00 LMNA (0.36) LMNACYP2C19HIF1ADRD3SLC6A3
SCHEMBL2745754 0.83 CA2 (0.35) LMNACYP2C19HIF1ADRD3SLC6A3
SCHEMBL25587280 0.83 POLB (0.33) LMNAALDH1A1POLBHDAC6KDM4E
SCHEMBL25587279 0.83 POLB (0.33) LMNAALDH1A1POLBHDAC6KDM4E
SCHEMBL25587275 0.83 POLB (0.33) LMNAALDH1A1POLBHDAC6KDM4E
SCHEMBL26023515 0.82 RIPK1 (0.42) LMNACYP2C19HIF1ADRD3SLC6A3
SCHEMBL20692421 0.80 LMNA (0.33) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL3139336 0.78 ALDH1A1 (0.46) LMNACYP2C19HIF1AALDH1A1EGFR
SCHEMBL27081436 0.78 ALDH1A1 (0.46) LMNACYP2C19HIF1AALDH1A1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US disclosed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US disclosed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US disclosed
US-20220089593-A1 PDE9 INHIBITOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-24 US disclosed
US-20210188775-A1 CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS GENENTECH, INC. (US) 2021-06-24 US disclosed
EP-2248820-B1 Universal supports for oligonucleotide synthesis GLEN RES CORP (US) 2014-01-08 EP disclosed
EP-1404695-B1 UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS GLEN RES CORP (US) 2013-04-10 EP disclosed
US-8178681-B2 methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency SHIONOGI & CO., LTD. (JP) 2012-05-15 US disclosed
EP-2248820-A1 Universal supports for oligonucleotide synthesis Glen Research Corporation (US) 2010-11-10 EP disclosed
US-7491817-B2 Universal supports for oligonucleotide synthesis GLEN RESEARCH CORPORATION (US) 2009-02-17 US disclosed
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative SHIONOGI & CO. LTD. (JP) 2008-05-01 US disclosed
US-20050250116-A1 Universal supports for oligonucleotide synthesis GLEN RESEARCH CORPORATION (US) 2005-11-10 US disclosed
US-6770754-B2 FUNCTIONALIZED POLYMERIC OR SILICA BASE MATERIAL; DO NOT INCLUDE A PRE-ATTACHED NUCLEOSIDE, AND THEREFORE CAN BE USED UNIVERSALLY FOR ANY NA OR RNA SYNTHESIS; FAST CLEAVAGE AND DEPHOSPHORYLATION AT RELATIVELY LOW TEMPERATURES GLEN RESEARCH COPORATION 2004-08-03 US disclosed
EP-1404695-A2 UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS Glen Research Corporation (US) 2004-04-07 EP disclosed
US-20020137855-A1 Universal supports for oligonucleotide synthesis GLEN RESEARCH CORPORATION (US) 2002-09-26 US disclosed
WO-2002044398-A2 UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS GLEN RESEARCH CORPORATION (US) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250116-A1 Universal supports for oligonucleotide synthesis FBL, NSUN2, NOP2 LMNA 1402/4885CYP2C19 3748/4885HIF1A 2627/4885
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 LMNA 1845/4885CYP2C19 4791/4885HIF1A 1972/4885
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative CNR1, CNR2, HRH4 LMNA 3604/4885CYP2C19 1098/4885HIF1A 3381/4885
US-20020137855-A1 Universal supports for oligonucleotide synthesis FBL, NSUN2, NOP2 LMNA 1368/4885CYP2C19 3800/4885HIF1A 2298/4885
US-20220089593-A1 PDE9 INHIBITOR AND USE THEREOF PDE9A, PDE12, PDE5A LMNA 1702/4885CYP2C19 57/4885HIF1A 1811/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP LMNA 2014/4885CYP2C19 4683/4885HIF1A 1789/4885
US-20210188775-A1 CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS TEAD2, TEAD1, SULT2A1 LMNA 4567/4885CYP2C19 336/4885HIF1A 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.